Aliqopa

Cupanisib drug description

Copanisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K), which primarily inhibits the PI3K-α and PI3K-δ isoforms expressed in malignant B cells. Aliqopa induces tumor cell death through apoptosis and inhibits the proliferation of primary malignant B cell lines. Aliqopa inhibits several key cell signaling pathways, including B cell receptor (BCR) signaling, CXCR12-mediated malignant B cell chemotaxis, and NFκB signaling in lymphoma cell lines.

Cupanisib usage and dosage

60 mg should be injected intravenously over 1 hour, and used on the 1st, 8th, and 15th days, and every 28 days is a cycle; adjust the dose when toxic reactions occur.

Kupanisi Warnings and Precautions

(1) Infection: Monitor patients for symptoms and signs of infection. For grade 3 or above infections, administration should be suspended until the situation is relieved.

(2) Hyperglycemia: Optimal blood sugar control should be achieved before each medication. Severe or persistent hyperglycemia should reduce or suspend medication.

(3) Hypertension: Administration should be stopped before systolic blood pressure is less than 150mmHg and diastolic blood pressure is less than 90mmHg. If antihypertensive drugs are needed, lowering the dose of ALIQOPA should be considered. Discontinue ALIQOPA if blood pressure cannot be controlled or life-threatening conditions develop.

(4) Non-infectious pneumonia (NIP): ALIQOPA dose reduction and symptomatic treatment. Patients who experience recurrent Grade 2 NIP or develop Grade 3 or higher NIP should permanently discontinue ALIQOPA.

(5) Neutropenia: Complete blood counts should be monitored at least weekly during treatment. Suspend medication before ANC ≥ 0.5×103 cells/mm3.

(6) Severe skin reactions: Severe or persistent skin reactions should suspend, reduce the dose, or terminate treatment.

(7) Embryo-fetal toxicity: May cause fetal harm. Inform patients of the potential risks to the fetus and to use effective contraception.

Copanisib drug interactions

(1)CYP3A inducers: Avoid combined use with strong CYP3A inducers.

(2)CYP3A inhibitor: If used in combination with a CYP3A inhibitor, reduce the dose of ALIQOPA to 45 mg.

Use of special populations in Kupanisi

Breastfeeding women: Discontinue medication or stop breastfeeding.